TAVR and surgery had similar 7-year composite outcomes (34.6% vs 37.2%).

Mortality, stroke, and rehospitalization rates were nearly identical between groups.

Valve durability matched: failure occurred in 6.9% (TAVR) vs 7.3% (surgery).

TAVR markedly reduced new-onset atrial fibrillation (17.7% vs 43.5%).

Higher risks after TAVR included LBBB, valve thrombosis, pacemaker implantation, and paravalvular regurgitation.

About 73% of both groups were alive without valve failure at 7 years.

Trial generalizability was limited; Edwards Lifesciences funded and contributed to study design and analysis.